Idiomas disponibles
Idiomas disponibles
3.
RAPIDFLAEM 6 PLUS NEBULISER DESCRIPTION
It is professional, quick and suited to administer all types of drugs, including
more costly ones, also in patients with chronic diseases. The RF6 PLUS
nebuliser features an optimal valve system which, combined with the
Nebulisation Manual Control, ensures an optimal therapeutic effect by maximising
the assimilation of medication by the lungs and minimising the amount of
medication dispersed in the surrounding environment. The configuration of
the internal lines of the RF6 PLUS nebuliser ensures the ideal granulometry
providing effective treatment right down to the lower airways.
During the inspiratory phase, by placing a finger over the hole of the Nebulisation
Manual Control compressed air is introduced into the nebuliser; at the same
time the inspiratory valve (A) of the nebuliser opens to permit entry of an
additional flow of air. The combination of these air flows increases the quantity
of medication nebulised and thus assimilated by the patient (MAXIMUM
ASSIMILATION OF MEDICATION). During the whole inspiratory phase the
expiratory valve (B) remains closed.
In the expiratory phase, removing the finger from the Nebulisation Manual
Control will cut off the flow of compressed air into the nebuliser and thus
interrupt the nebulisation of drug; at the same time the inspiratory valve (A)
will close, preventing the nebulised mist from being discharged from the
nebuliser and dispersed in the surrounding environment (MINIMUM WASTE
OF MEDICATION). The air exhaled by the patient will be released through the
valve (B), which opens automatically during the expiratory phase while the
mouthpiece remains in the mouth.
NON-SPILL SYSTEM
The RF6 PLUS nebuliser is specially suitable also for pediatric use, since the
non-spill system prevents medication from spilling out even if the nebuliser
is accidentally turned upside-down.
(Efficacy tested up to 5 ml, the average dose recommended for normal use)
Technical details
- Minimum capacity:
- Max tank capacity :
- * Max delivery:
* Average values measured with 0.9% saline solution in compliance with Flaem internal procedure.
In vitro characterization carried out at the
Inamed Research GmbH & Co. KG on
behalf of TÜV Rheinland Product Safety
GmbH – Germany in compliance with the
new European Standard for aerosol therapy
appliances, Standard EN 13544-1.
- MMAD:
- Breathable fraction < 5 µm: 76 %
For more complete data, directly contact
Flaem Nuova S.p.A
2 ml
8 ml
0.54 ml/min approx.
2.8 µm
MMAD
9
INSPIRATORY PHASE
.A.
.B.
.10.
.8.
EXPIRATORY PHASE
.B.
.10.
.8.
.A.
